Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2007

Stemline Therapeutics In-Licenses Oncology Compound

  • Stemline Therapeutics in-licensed the exclusive worldwide rights to SL-401, a Phase I compound directed at a cancer stem cell target from the Scott & White Cancer Research Institute/Texas A&M Health Science Center College of Medicine. SL-401 has reportedly demonstrated single agent antitumor activity in a multicenter, dose-escalation study.

    SL-401 targets the interleukin-3 receptor (IL-3R) and has been shown to impair the ability of cancer stem cells to form tumors.  IL-3R is over-expressed on multiple hematological cancers. In AML, IL-3R is over-expressed on both leukemia blasts as well as leukemia cancer stem cells.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »